Standard BioTools Inc. (LAB)

Compare

1.1150

-0.0450

(-3.88%)

As of 2:44:10 PM EDT. Market Open.

Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know

It's been a mediocre week for Standard BioTools Inc. ( NASDAQ:LAB ) shareholders, with the stock dropping 18% to...

Simply Wall St. last month

LAB
-3.88%
Standard BioTools to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual Healthcare Conference - March 3rd – 5th, 2025 Presenting on Monday, March 3, 2025, at 3:10 p.m. ET2025 Leerink Partners Global Healthcare Conference - March 9th – 12th, 2025Participating in investor meetings on March 12thKeyBanc’s 5th Annual Healthcare Forum – March 18th & 19th, 2

GlobeNewswire last month

LAB
-3.88%
Q4 2024 Standard BioTools Inc Earnings Call

Q4 2024 Standard BioTools Inc Earnings Call

Thomson Reuters StreetEvents last month

LAB
-3.88%
Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Despite a decline in overall revenue, Standard BioTools Inc (LAB) showcases resilience with cost reductions, strategic partnerships, and a robust cash position.

GuruFocus.com last month

LAB
-3.88%
Standard BioTools: Q4 Earnings Snapshot

The South San Francisco, California-based company said it had a loss of 9 cents per share. Losses, adjusted for stock option expense and amortization costs, came to 5 cents per share. The company that makes equipment to control fluids posted revenue of $46.7 million in the period.

Associated Press Finance last month

LAB
-3.88%
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million

GlobeNewswire last month

LAB
-3.88%
Shareholders in Standard BioTools (NASDAQ:LAB) have lost 66%, as stock drops 10.0% this past week

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...

Simply Wall St. last month

LAB
-3.88%
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412)

GlobeNewswire last month

LAB
-3.88%
Strength Seen in American Well (AMWL): Can Its 18.8% Jump Turn into More Strength?

American Well (AMWL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 2 months ago

AMWL

LAB
-3.88%
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024. Standard BioTools expects fourth quarter 2024 revenue of appro

GlobeNewswire 2 months ago

LAB
-3.88%
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trialsSOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of Nature Medicine titled “Proteomic changes upon treatment with s

GlobeNewswire 2 months ago

LAB
-3.88%
In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$56m market cap drop, institutional owners may be forced to take severe actions

Key Insights Given the large stake in the stock by institutions, Standard BioTools' stock price might be vulnerable to...

Simply Wall St. 3 months ago

LAB
-3.88%
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live audio webcast will be available to investors and other inte

GlobeNewswire 3 months ago

LAB
-3.88%
Standard BioTools Appoints Alex Kim as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization.

GlobeNewswire 4 months ago

LAB
-3.88%
Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17

A week ago, Standard BioTools Inc. ( NASDAQ:LAB ) came out with a strong set of third-quarter numbers that could...

Simply Wall St. 5 months ago

LAB
-3.88%
Standard BioTools Third Quarter 2024 Earnings: Beats Expectations

Standard BioTools ( NASDAQ:LAB ) Third Quarter 2024 Results Key Financial Results Revenue: US$45.0m (up 77% from 3Q...

Simply Wall St. 5 months ago

LAB
-3.88%
Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ...

Despite a decline in overall revenue, Standard BioTools Inc (LAB) shows resilience with strong consumables growth and improved operational efficiencies.

GuruFocus.com 5 months ago

LAB
-3.88%
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates

Standard BioTools (LAB) delivered earnings and revenue surprises of 37.50% and 7.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

LAB
-3.88%
Standard BioTools: Q3 Earnings Snapshot

LAB) on Wednesday reported a loss of $26.9 million in its third quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 7 cents. Losses, adjusted for stock option expense and restructuring costs, were 5 cents per share.

Associated Press Finance 5 months ago

LAB
-3.88%
Standard BioTools Reports Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully reali

GlobeNewswire 5 months ago

LAB
-3.88%

Performance Overview

Return	LAB	S&P 500 (^GSPC)
YTD	-36.29%	-9.69%
1-Year	-60.74%	+2.93%
3-Year	-70.66%	+18.35%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Standard BioTools Inc. (LAB)

Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Standard BioTools to Participate in Upcoming Investor Conferences

Q4 2024 Standard BioTools Inc Earnings Call

Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Standard BioTools: Q4 Earnings Snapshot

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Shareholders in Standard BioTools (NASDAQ:LAB) have lost 66%, as stock drops 10.0% this past week

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Strength Seen in American Well (AMWL): Can Its 18.8% Jump Turn into More Strength?

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$56m market cap drop, institutional owners may be forced to take severe actions

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17

Standard BioTools Third Quarter 2024 Earnings: Beats Expectations

Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ...

Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates

Standard BioTools: Q3 Earnings Snapshot

Standard BioTools Reports Third Quarter 2024 Financial Results

Performance Overview